By regulating a large number of genes (more than 500) capable of manipulating tumor metabolism, the wild-type or mutant status of p53 may have different effects on tumor metabolism and, consequently, indirectly on resistance to therapeutic agents. This evidence concerns the gene TP53 and neoplasm.